Get notified when TGTX files again. Create a free account and we'll email you the moment its next filing is analyzed.
Get filing alertsTG Therapeutics reports positive Phase 1 data for subcutaneous version of BRIUMVI
Filed June 3, 2026 · Period ending June 3, 2026 · ~1 min read
Key Changes
-
high
Phase 1 trial of subcutaneous ublituximab (BRIUMVI's active ingredient) showed positive pharmacokinetic, pharmacodynamic, safety, and tolerability results in relapsing MS patients. A subcutaneous formulation could offer more convenient dosing than current infusion.
Press Release (June 3, 2026) view on EDGAR → -
high
This represents a potential product line extension for BRIUMVI, the company's approved multiple sclerosis treatment, with a delivery method that may improve patient compliance and expand market opportunity.
Press Release (June 3, 2026) view on EDGAR →
This preview is just the start — the full report includes the narrative summary, section-by-section diffs against the prior filing, and verbatim quotes with EDGAR citations.
Want to see a complete report first? Today's free report (PXED 10-Q) is open in full — no account needed.
Partner
Trade TGTX commission-free
Open an account, get a free stock.
Investing involves risk. Free stock terms apply.
Thanks — your feedback helps us improve report quality.
Source-verified from EDGAR · Narrative written by AI · Jun 3, 2026 · How we verify